Correction to: Diabetologia
Owing to an oversight, the authors omitted to note that Dr Taub is a co-founder of and equity holder in Cardero Therapeutics. A corrected version of the relevant section is given in full here:
This work was supported by grants from: Merit Review Award IO1CX000635-01A1 from the United States Department of Veterans Affairs Clinical Sciences Research and Development Service; HHS/NIH/NIDDK (DK098717-01A1); Spanish Ministry of Economy, Industry and Competitiveness (Ministerio de Economía, Industria y Competitividad, MINECO), Spain (SAF2013-41945-R and SAF2016-76028R); Comunidad de Madrid, Spain (S2011/BMD-2402); Centro de Investigación Biomédica en Red (CIBER) de Enfermedades Raras, Spain (CB06/07/0017). LF is supported by the Ramón y Cajal Spanish programme (call of 2013). FV is a Cardero Therapeutics co-founder and stockholder and PT is a Cardero Therapeutics co-founder and equity holder.
Author information
Authors and Affiliations
Corresponding author
Additional information
The online version of the original article can be found at https://doi.org/10.1007/s00125-017-4379-z
Rights and permissions
About this article
Cite this article
Formentini, L., Ryan, A.J., Gálvez-Santisteban, M. et al. Correction to: Mitochondrial H+-ATP synthase in human skeletal muscle: contribution to dyslipidaemia and insulin resistance. Diabetologia 61, 2674 (2018). https://doi.org/10.1007/s00125-018-4747-3
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00125-018-4747-3